Advanced non–small cell lung carcinoma (NSCLC) is an incurable disease that is associated with a poor prognosis. Globally, it is the leading cause of cancer-related death.
1 Docetaxel has been the standard of care for advanced NSCLC following disease progression with platinum doublet chemotherapy.
2,3 However, docetaxel is associated with only modest efficacy but substantial toxicity. With the recent advancement in immune checkpoint inhibitor therapies
4-8 that target the PD-L1 (programmed cell death 1 ligand 1) and PD-1 (programmed cell death 1) pathways, these agents have recently replaced docetaxel as the new standard second or later line of treatment.